drug

Anakinra for RA and Refractory Idiopathic Recurrent Pericarditis
Anakinra for RA and Refractory Idiopathic Recurrent PericarditisCardiac Matters—What you need to know about anakinra
Report: Specialty drugs unaffordable for consumersA new AARP report shows that the rapid rise in cost of specialty drugs exceeds median family income.
High cost of new PCSK9 inhibitors could plague payersThe high cost of these medications could overwhelm patients and plans, according to one expert.
New cholesterol-lowering drugs draw attentionFirst injectable cholesterol drugs approved
FDA’s First Biosimilar Approval Draws Excitement, ConcernThe FDA has approved filgrastim-sndz (Zarxio, Sandoz), treating patients at increased risk of neutropenia, but it's stirring up mixed emotions. Learn why
HealthPocket study finds copayments, coinsurance fees for drugs rise under ACAAn examination of new health plans from 46 states revealed that copayments and co-insurance fees for drugs increased an average of 34% as compared to the pre-Affordable Care Act (ACA) individual insurance market.
Industry relationships influence MD prescribing behaviorSocial ties to industry appear to influence physician prescribing behaviors, according to a recent study published online January 7 in JAMA Internal Medicine (formerly Archives of Internal Medicine).
FDA recommends lower dose of zolpidem for patient safetyIn a drug safety communication, FDA has recommended that the bedtime dose of zolpidem, for the treatment of insomnia, be lowered because new data show that blood levels in some patients may be high enough the morning after use to impair activities that require alertness, including driving.
Color of generic drugs may affect medication adherenceChanges in tablet color significantly increase the odds that patients will stop taking their medications, according to a study published online first Dec. 31, 2012, in JAMA Internal Medicine (formerly known as the Archives of Internal Medicine).